Cannabis Science Inc (OTCMKTS:CBIS) has come a long way since it was trading just over $0.01 a share this time last year. The stock has seen double digit gains as pot stocks have heated up across the board. The Company is one of the original Marijuana plays to hit the BB’s back in 2009. Over the past several years as Marijuana stocks have heated up CBIS has been at the forefront of this incredible phenomenon trading massive volume and rising to incredible highs.
CBIS is at the right place at the right time; pot stocks have heated up going into the election and following Trumps upset. The red hot Marijuana industry has quickly turned into a multi-billion dollar massive growth market that is sweeping across the Country with many new states legalizing the drug including California, Nevada, Maine, and Massachusetts on November 8. Medical MJ products in the U.S. alone are projected to generate up to $35 Billion by 2020.
Cannabis Science Inc (OTCMKTS:CBIS) works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness.
CBIS initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Several years ago CBIS made a number of acquisitions in the cannabis sector that currently drive future growth. CBIS 2 most important drugs in development are:
The CS-S/BCC-1 drug program was launched in 2011 due to the “apparent success in 4 skin cancer patients who have self-administered cannabinoid based extracts topically to their skin cancers. These patients have experienced shrinking and apparent eradication of their skin cancer lesions.”
The drug CS-TATI-1 aims to target patients with drug-resistant HIV strains. The earliest article I could find relating to the launch of this program was in June 5, 2012, where the company loosely described a mission to “explore the commercial development of Phyto cannabinoid-based therapeutics for drug resistant HIV infection.”
To Find out the inside Scoop on CBIS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Back in March CBIS commented on the recent success of GW Pharmaceuticals in their phase three testing of a CBD-based product designed to treat patients with a rare form of epilepsy.
The successful trials in Europe help pave the way for companies like Cannabis Science to move forward with their own testing in Europe and in the United States. It will also allow for a quicker regulatory process due to more research being made available for regulators and more experience with these types of treatments.
CBIS is working diligently to continue testing and providing limited rollouts for its own CBD-based treatment products in California at the moment. On the heels of GW Pharmaceuticals’ success, the company is more confident than ever in its planned wide-scale rollout, which will include a wider array of near term clinical drug development programs in California, possibly Washington, and the Netherlands.
On March 2 CBIS announced its President, CEO and Co-Founder, Raymond C. Dabney, will be a keynote speaker and panelist at the Global Health Catalyst (GHC) Summit at Harvard Medical School on April 28-30, 2017. Additionally, Cannabis Science’s Chief Medical Officer (CMO), Allen Herman, will Co-Chair a special session at the GHC Summit. Both Dabney and Herman previously presented at Harvard Medical School in November 2016.
Dabney will be the keynote speaker and a panelist for a special session on “Cannabis Science Versus Cancer and Other Malignancies.” Dabney will discuss how cannabinoids can be used to treat cancer and other diseases, manage the side effects of cancer treatment like radiotherapy and chemotherapy, and potential applications of medical cannabis in global health to close the global pain divide; Cannabis Science’s vision for the global health and development impact of cannabinoid-based medicines; and the need for greater public education on the importance of medical cannabis research.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $279 million market valuation CBIS has little assets or revenues and rising short term debt that has resulted in dilution over the years. But CBIS is an exciting story developing in small caps; the Company is specializing in the development of cannabis-based medicines and has a number of new exciting initiatives in the booming pot sector. CBIS is currently testing and providing limited rollouts for its own CBD-based treatment products in California at the moment. CBIS is one of the original pot stocks with a long history of making spectacular 2000% plus moves that knows how to get its story into the national media. CBIS is a great place to be when pot stocks heat up as they are right now leading up to November 8. We will be updating on CBIS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CBIS.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in CBIS either long or short and we have not been compensated for this article.